Medical Condition News

RSS

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.

20 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

High dietary salt intake and obesity together trigger abnormal activation of cellular protein

Dietary salt intake and obesity are two important risk factors in the development of high blood pressure. Each packs its own punch, but when combined, they deliver more damage to the heart and kidneys than the sum of their individual contributions.

19 Sep 2011

Laser Med Center receives FDA approval for device to treat Trigeminal Neuralgia

Laser Med Center, which specializes in treating Trigeminal Neuralgia, has received an FDA approval for its revolutionary laser device. This is a non-invasive alternative to surgery, which treats pain through nerve tissue regeneration.

19 Sep 2011

Prevalence of diabetes increases 30% over last four years in urban India

The prevalence of diabetes in urban India is accelerating at a rapid rate and now stands at 5.5 percent (just under 20 million people), compared with 4.6 percent in 2007 - equivalent to a 30 percent increase in actual population numbers over the last four years - according to new research by GfK HealthCare's Roper Global Diabetes Group. Moreover, a full 10 percent of these patients have been diagnosed in the past 12 months.

19 Sep 2011

Scientists discover common genetic variants associated with schizophrenia and bipolar disorder

Common genetic variants contribute to the risk of schizophrenia and bipolar disorder, an international research consortium has discovered.

19 Sep 2011

Amneal announces availability of generic antiepileptic drug, Felbamate

Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.

19 Sep 2011

Boston Scientific introduces Coyote Balloon Catheter for peripheral angioplasty

Boston Scientific Corporation has launched its Coyote Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The Company has begun marketing the product in the U.S., Europe and other international markets.

19 Sep 2011

Enrollment commences in MINI-AMI study of Impella in STEMI patients

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the first patient enrolled in MINI-AMI, an FDA prospective, randomized, controlled multi-center study to assess the role of 24-hours of direct unloading of the left ventricle with Impella 2.5 support to reduce infarct size in patients with ST-elevation myocardial infarction (STEMI) without cardiogenic shock.

19 Sep 2011

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.

19 Sep 2011

OptiScan's new bedside glucose monitoring system receives European CE Mark

OptiScan Biomedical Corporation, a developer of innovative continuous glucose monitoring systems for use in intensive care units (ICU), today announced that the company's OptiScanner Automatic Bedside Glucose Monitoring System has received CE Mark certification for use in the European Union.

19 Sep 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011

Study investigates links between GWI and veterans' locations during war

Gulf War Illness (GWI)-the chronic health condition that affects about one in four military veterans of the 1991 Gulf War-appears to be the result of several factors, which differed in importance depending upon the locations where veterans served during the war, according to a Baylor University study.

19 Sep 2011

Researcher identifies genetic mutation responsible for adermatoglyphia

Like DNA, fingerprints are unique to each person or set of identical twins. That makes them a valuable identification tool for everything from crime detection to international travel. But what happens when the tips of our fingers are missing those distinctive patterns of ridges?

19 Sep 2011

ESMO honors three medical oncologists for cancer care and research

The European Society for Medical Oncology (ESMO) has honored three of Europe's leading medical oncologists with prestigious awards recognizing their achievements in clinical care and research.

19 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

ESC urges European heads of state to prevent chronic non-communicable diseases

The European Society of Cardiology, through the European Chronic Disease Alliance (ECDA), has urged European heads of state "to show leadership" and long-term commitment to the prevention of chronic non-communicable diseases at today's "high level meeting" of the UN General Assembly in New York.

19 Sep 2011

Meda acquires exclusive licensing rights to Nalox from Moberg Derma

Meda has acquired exclusive licensing rights to Nalox (treatment of fungal nail infections/nail psoriasis) from Moberg Derma AB.

19 Sep 2011

Karo Bio receives approval to initiate eprotirome phase III study in HeFH

Karo Bio AB has received approval from national regulatory authorities to start its phase III patient study with eprotirome, enabling the study to start as planned with an Investigators meeting in September.

19 Sep 2011

Low-dose anticholinergic drugs do not appear to cause cognitive impairment in dementia patients

Researchers whose findings on the detrimental impact of some common medicines on elderly people were widely reported earlier in the summer have found that taking a few of these medicines does not appear to cause further cognitive impairment in those already suffering from dementia.

19 Sep 2011